Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRON Cronos Group	$2.14 +2.4%	$1.99	$1.60 ▼ $2.54	$806.08M	1.03	1.37 million shs	1.60 million shs
NLTX Neoleukin Therapeutics	$22.34 -1.2%	$19.01	$2.03 ▼ $14.36	$209.95M	1.11	50,104 shs	111,114 shs
SNDX Syndax Pharmaceuticals	$10.31 +6.0%	$9.86	$8.58 ▼ $25.07	$837.24M	0.7	1.88 million shs	1.89 million shs
TRVI Trevi Therapeutics	$7.00 +2.6%	$6.25	$2.36 ▼ $7.48	$799.94M	0.46	1.49 million shs	1.75 million shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRON Cronos Group	+2.39%	+5.94%	+15.05%	+19.55%	-14.06%
NLTX Neoleukin Therapeutics	0.00%	+0.36%	+25.79%	+61.53%	-48.43%
SNDX Syndax Pharmaceuticals	+5.96%	+11.94%	+8.76%	-20.78%	-55.92%
TRVI Trevi Therapeutics	+2.64%	+2.04%	+17.45%	+11.64%	+149.11%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRON Cronos Group	2.0528 of 5 stars	0.0	4.0	0.0	0.0	2.5	0.0	2.5
NLTX Neoleukin Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SNDX Syndax Pharmaceuticals	3.4024 of 5 stars	3.5	0.0	0.0	4.4	2.9	0.8	0.0
TRVI Trevi Therapeutics	3.5641 of 5 stars	4.7	5.0	0.0	0.0	0.6	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRON Cronos Group	0.00	N/A	N/A	N/A
NLTX Neoleukin Therapeutics	0.00	N/A	N/A	N/A
SNDX Syndax Pharmaceuticals	2.90	Moderate Buy	$34.10	230.75% Upside
TRVI Trevi Therapeutics	3.30	Buy	$20.88	198.21% Upside

Current Analyst Ratings Breakdown

Latest NLTX, TRVI, SNDX, and CRON Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/15/2025	SNDX Syndax Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$37.00 ➝ $35.00
7/10/2025	SNDX Syndax Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$18.00
7/1/2025	TRVI Trevi Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$25.00
6/2/2025	TRVI Trevi Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
6/2/2025	TRVI Trevi Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$21.00
5/28/2025	TRVI Trevi Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy ➝ Buy	$21.00
5/20/2025	TRVI Trevi Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$24.00 ➝ $24.00
5/6/2025	SNDX Syndax Pharmaceuticals	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$16.00 ➝ $17.00
5/6/2025	SNDX Syndax Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00 ➝ $32.00

(Data available from 7/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRON Cronos Group	$117.61M	7.02	$0.00 per share	4,491.53	$2.90 per share	0.74
NLTX Neoleukin Therapeutics	N/A	N/A	N/A	N/A	$11.08 per share	N/A
SNDX Syndax Pharmaceuticals	$23.68M	37.47	N/A	N/A	$3.38 per share	3.05
TRVI Trevi Therapeutics	N/A	N/A	N/A	N/A	$1.30 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRON Cronos Group	$41.08M	$0.13	16.46	71.33	N/A	39.69%	-0.07%	-0.07%	8/6/2025 (Estimated)
NLTX Neoleukin Therapeutics	-$57.56M	-$3.11	N/A	∞	N/A	N/A	-37.22%	-30.91%	N/A
SNDX Syndax Pharmaceuticals	-$318.76M	-$3.86	N/A	N/A	N/A	-757.53%	-101.60%	-58.41%	8/7/2025 (Estimated)
TRVI Trevi Therapeutics	-$47.91M	-$0.45	N/A	N/A	N/A	N/A	-58.41%	-52.52%	8/6/2025 (Estimated)

Latest NLTX, TRVI, SNDX, and CRON Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	CRON Cronos Group	-$0.02	N/A	N/A	N/A	N/A	N/A
8/14/2025	Q2 2025	TRVI Trevi Therapeutics	-$0.10	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	SNDX Syndax Pharmaceuticals	-$0.99	N/A	N/A	N/A	N/A	N/A
5/8/2025	Q1 2025	CRON Cronos Group	$0.01	$0.02	+$0.01	$0.02	$45.44 million	$33.62 million
5/6/2025	Q1 2025	TRVI Trevi Therapeutics	-$0.13	-$0.09	+$0.04	-$0.09	N/A	N/A
5/5/2025	Q1 2025	SNDX Syndax Pharmaceuticals	-$1.04	-$0.98	+$0.06	-$0.98	$15.88 million	$20.04 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRON Cronos Group	N/A	N/A	N/A	N/A	N/A
NLTX Neoleukin Therapeutics	N/A	N/A	N/A	N/A	N/A
SNDX Syndax Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TRVI Trevi Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRON Cronos Group	N/A	27.80	26.75
NLTX Neoleukin Therapeutics	N/A	15.33	15.33
SNDX Syndax Pharmaceuticals	1.53	5.80	5.75
TRVI Trevi Therapeutics	N/A	15.38	15.38

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRON Cronos Group	8.71%
NLTX Neoleukin Therapeutics	52.37%
SNDX Syndax Pharmaceuticals	N/A
TRVI Trevi Therapeutics	95.76%

Insider Ownership

Company	Insider Ownership
CRON Cronos Group	6.90%
NLTX Neoleukin Therapeutics	1.58%
SNDX Syndax Pharmaceuticals	4.10%
TRVI Trevi Therapeutics	18.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRON Cronos Group	450	385.68 million	359.07 million	Optionable
NLTX Neoleukin Therapeutics	90	9.40 million	9.25 million	No Data
SNDX Syndax Pharmaceuticals	110	86.05 million	82.52 million	Optionable
TRVI Trevi Therapeutics	20	117.29 million	95.83 million	Optionable

NLTX, TRVI, SNDX, and CRON Headlines

Recent News About These Companies

Wall Street Analysts Predict a 231.05% Upside in Trevi Therapeutics (TRVI): Here's What You Should Know

July 11, 2025 | zacks.com

Trevi Therapeutics (NASDAQ:TRVI) Trading 6.1% Higher - Time to Buy?

July 9, 2025 | marketbeat.com

Trevi Therapeutics (NASDAQ:TRVI) Trading Down 3.7% - Should You Sell?

July 3, 2025 | marketbeat.com

Analysts Offer Predictions for TRVI FY2025 Earnings

July 3, 2025 | marketbeat.com

Cantor Fitzgerald Initiates Coverage of Trevi Therapeutics (TRVI) with Overweight Recommendation

July 2, 2025 | msn.com

TRVI Trevi Therapeutics, Inc. - Seeking Alpha

July 1, 2025 | seekingalpha.com

Cantor Fitzgerald Initiates Coverage on Trevi Therapeutics (NASDAQ:TRVI)

July 1, 2025 | marketbeat.com

Trevi Therapeutics to Attend Leerink Partners Therapeutics Forum: I&I and Metabolism

July 1, 2025 | prnewswire.com

TRVI STOCKHOLDER ALERT: Kaskela Law LLC Announces Investigation of Trevi Therapeutics, Inc. (NASDAQ: TRVI) and Encourages Long-Term Investors to Contact the Firm

June 26, 2025 | globenewswire.com

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Consensus Recommendation of "Buy" by Analysts

June 26, 2025 | marketbeat.com

Trevi Therapeutics (NASDAQ:TRVI) Shares Down 4% - Time to Sell?

June 25, 2025 | marketbeat.com

TRVI - Trevi Therapeutics Inc Key Metrics - Morningstar

June 24, 2025 | morningstar.comM

Trevi Therapeutics Stockholders Approve Key Amendments

June 17, 2025 | tipranks.com

Trevi Therapeutics Announces Closing of $115 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

June 5, 2025 | prnewswire.com

Trevi Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock

June 3, 2025 | prnewswire.com

Trevi Therapeutics Announces Proposed Public Offering of Common Stock

June 2, 2025 | prnewswire.com

Trevi Therapeutics Showcases Drug That Cuts Cough Frequency In Lung Disease Patients

June 2, 2025 | benzinga.com

Trevi Therapeutics Announces Positive Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough

June 2, 2025 | prnewswire.com

Trevi Therapeutics to Host Conference Call and Webcast on June 2nd to Share Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough

June 1, 2025 | prnewswire.com

H.C. Wainwright Initiates Coverage of Trevi Therapeutics (TRVI) With Buy Rating

May 29, 2025 | msn.com

Trevi Therapeutics to Participate in Upcoming June Conferences

May 29, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NLTX, TRVI, SNDX, and CRON Company Descriptions

Cronos Group NASDAQ:CRON

$2.14 +0.05 (+2.39%)

Closing price 07/22/2025 04:00 PM Eastern

Extended Trading

$2.15 +0.01 (+0.56%)

As of 04:00 AM Eastern

Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.

Neoleukin Therapeutics NASDAQ:NLTX

$22.34 -0.26 (-1.15%)

As of 07/18/2025

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.

Syndax Pharmaceuticals NASDAQ:SNDX

$10.31 +0.58 (+5.96%)

Closing price 07/22/2025 04:00 PM Eastern

Extended Trading

$10.14 -0.17 (-1.61%)

As of 07/22/2025 06:52 PM Eastern

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

Trevi Therapeutics NASDAQ:TRVI

$7.00 +0.18 (+2.64%)

Closing price 07/22/2025 04:00 PM Eastern

Extended Trading

$7.00 0.00 (0.00%)

As of 07/22/2025 06:15 PM Eastern

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time